(hereinafter referred to as “Juventas”) announced that its independently developed CAR-T cell therapy product, Inaticabtagene Autoleucel (Ina-cel) (tradename: YORWIDATM), has received new drug ...

The ACR issued a 2025 guideline for the treatment of SLE that addressed treatment and management of specific organ system ...

A SIX-year-old girl was seen at the United States Army Hospital, Fort Rucker, Alabama, with a chief complaint of mild jaundice and dark urine present for one day. The child had previously been seen by ...

Agios Pharmaceuticals, Inc. drops after mixed Phase 3 mitapivat results in Sickle Cell Disease. Click here to find out why ...

In its mission to grow the reach of its pyruvate kinase (PK) activator Pyrukynd (mitapivat), Agios Pharmaceuticals has come up short of producing an unequivocal win in the key indication of sickle | ...

The B-FREE Chronic Babesiosis Study ( NCT06656351) is a Phase 2 open-label study that will evaluate the efficacy (and safety) of the ARAKODA ® regimen of tafenoquine over 90 days for resolution of ...

By contrast, Aduro’s Hydrochemolytic™ Technology achieves the transformation of plastics-to-liquid hydrocarbons with much ...

Trial met primary endpoint of hemoglobin response and key secondary endpoints of change from baseline in hemoglobin concentration and indirect ...

Agios Pharmaceuticals plans to share data from RISE UP with the Food and Drug Administration to support the approval of the sickle cell disease indication.

This latest corporate clash has Alkermes working to beat back a challenge from H. Lundbeck for sleep disorder drug developer Avadel Pharmaceuticals.

Hydrochemolytic oil was processed "as is" without hydrotreatment or dilution achieved stable furnace operation, and olefin ...

Trial met primary endpoint of hemoglobin response and key secondary endpoints of change from baseline in hemoglobin concentration and indirect bilirubin Trial showed trend favoring mitapivat but did ...